Diagnostics company bioMerieux (PARIS:BIM) has received 510(k) clearance from the U.S. Food and Drug Administration for a test to detect and screen for methicillin-resistant staphylococcus, more ...

bioMérieux, French manufacturer of diagnostic solutions, has received FDA 510(k) approval for NucliSENS EasyQ MRSA, an automated molecular test for MRSA, according to a company news release. The test ...

Company Offers Most Comprehensive, Cost-Effective Suite of Solutions to Detect and Screen for Methicillin Resistant Staphylococcus aureus (MRSA) “bioMérieux is committed to bringing innovative ...

The Food and Drug Administration (FDA) has authorized marketing of a new diagnostic test, cobas vivoDx MRSA (Roche Molecular Systems Inc), to detect methicillin-resistant Staphylococcus aureus (MRSA) ...

The US Food and Drug Administration (FDA) has approved a new, faster diagnostic test based on bacterial viability and a novel technology to detect methicillin-resistant Staphylococcus aureus (MRSA) ...

An infectious disease test developer has raised $1.9 million in a series B financing round to advance its MRSA screening panel. It will also use the funds to develop its new molecular diagnostic ...

Antibiotic resistance continues to push modern medicine into dangerous territory. In hospitals around the world, infections ...

Detect-Ready assay requires swab DNA and provides results in three hours. Molecular Detection (MDI) appointed Launch Diagnostics as the exclusive distributor for its Detect-Ready™ MRSA assay in the ...

For the first time, Illinois hospitals have released data on the rates of Clostridium difficile and methicillin-resistant Staphylococcus aureus from lab results. This data is available on the Illinois ...

The Illinois Department of Public Health announced the publication of the first infection surveillance data on Clostridium difficile and methicillin-resistant Staphylococcus aureus rates from lab ...